The civil servant drew attention to vaccinations falling to lowest level in a decade
News
NICE releases revised guidelines on antidepressants
The new guidelines focus on key areas of prescription, management of withdrawal and severity of withdrawal symptoms
Oncomatryx announces 15m euros funding to conduct clinical trials
Company at the forefront of developing personalised treatments against invasive cancer has raised 15m euros to conduct clinical trials
New coalition formed to raise awareness of sight loss
‘The Eyes Have It’ partnership will highlight the importance of eye health
Shionogi and NEC collaborate on hepatitis B vaccine
High unmet need in the area of hepatitis B therapies will see companies share responsibilities to develop the vaccine
King’s College London explore COVID-19 technology as heart attack cure
Protein technology could dramatically improve prospects of heart attack victims by proliferating organ cells
NICE recommends Merck’s Tepmetko for lung cancer treatment
Approval demonstrates significant step forward in the treatment of adult advanced NSCLC patients with METex14
ISA Pharmaceuticals announce new trial testing technology for cancers
Trial of Amplivant will begin in a number of cancer patients including those with ovarian cancer
Ampersand Health and UCB partner in new arthritis initiative
Companies will support a study which provides vital information on arthritis for patient-supporting HCPs
Cannabis firm launches UK clinic following prescription license allocation
Cantourage has appointed cannabis prescribers and is now officially operational via a new centre
Engetix and Takeda announce expanded collaboration for anti-fibrotic therapies
Engitix and Takeda will extend existing agreement to collaborate extensively in the development of therapeutics in IBD
Novacyt PCR COVID-19 test approved under CTDA legislation
Novacyt’s second direct-to-PCR test is the third product to be added to the Coronavirus Test Device Approvals (CTDA) register of approved products
Catalent acquires Oxfordshire facility to expand biologics in UK and Europe
The biologics development and manufacturing facility is currently under construction near Oxford, UK
NICE overturns previous decision, recommends Merck and Pfizer’s Bavencio
Following successful appeals, the therapy has been recommended for all eligible bladder cancer patients
NICE recommends Koselugo for the treatment of neurofibromatosis type 1
Alexion Pharma UK, AstraZeneca’s Rare Disease group, announces the recommendation of its pivotal neurofibromatosis treatment
